

#8  
1/23/96RECEIVED  
JAN 22 1996  
GROUP 1800Docket No.: 434-047PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Chatterjee et al.

Serial No. 08/372,676

Filed: January 17, 1995

For: ANTI-IDIOTYPE MONOCLONAL ANTIBODY 1A7 AND USE FOR THE  
TREATMENT OF MELANOMA AND SMALL CELL CARCINOMA:  
:  
:  
:  
Group Art Unit: 1806  
:  
Examiner: Reeves, J.  
:SUPPLEMENTAL RESPONSE UNDER 37 CFR § 1.111Honorable Commissioner of  
Patents and Trademarks  
Washington, D. C. 20231

Sir:

## Certification of Facsimile Transmission

I hereby certify that this paper is being facsimile  
transmitted to the Patent and Trademark Office  
on the date shown below.

Drew R. Herndon

Type or print name of person signing certification

D.R. Herndon 1-3-96

Signature Date

This Supplemental Amendment clarified certain remarks made in  
an Amendment filed by the Applicants under 37 CFR § 1.111 on  
November 8, 1995.

In replying to the Examiner's rejection of claims 1-3 under 35  
USC § 102(b) over an abstract by Chatterjee et al., the amendment  
states: "[T]he 1A1-1A7 antibody disclosed in the abstract is not  
identical to the 1A7 antibody proposed in the Patent Application"  
(amendment, page 10, ¶ 2, emphasis in original). This statement is  
meant to refer to a preparation of antibodies obtained from the  
1A1-1A7 cell line, which is contrasted with a preparation of  
antibodies from the cell line deposited with the ATCC in support of  
the present application.

The amendment goes on to relate that limiting dilution cloning  
was performed following the publication of the abstract. The

Serial No. 08/372,676

cultured hybridoma line described in the abstract had been obtained by a single round of dilution cloning. It was therefore possible that the 1A1-1A7 cell line comprised contaminating cells. If the contaminating cells were immunoglobulin-producing cells, then any 1A7 preparation from the cells could comprise immunoglobulin from the contaminating cells.

The 1A7-producing hybridoma line was re-cloned by two rounds of limiting dilution before being deposited with the ATCC in support of the present application. As a result, the clonality of the cell line (and hence the stability of the line) may have been improved, and the ability to obtain a preparation of 1A7 or higher purity may have been enhanced.

However, the recloning of the cell line is not expected to have affected the 1A7 producing cells comprised in the hybridoma cells described in the abstract.

Favorable consideration of the Supplemental Amendment is requested prior to the January 25, 1996, interview date.

Respectfully submitted,

LOWE, PRICE, LEBLANC & BECKER

*Demetra J. Mills*

Demetra J. Mills

Registration No. 34,506

99 Canal Center Plaza, Suite 300  
Alexandria, Virginia 22314  
(703) 684-1111 DJM:drh  
Date: January 3, 1996

**Certification of Facsimile Transmission**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Drew R. Herndon  
Type or print name of person signing certification  
D.R. Herndon 1-3-96  
Signature Date